Compare Alteris Therapeutics vs Orca Therapeutics
Customers evaluate the quality of Alteris Therapeutics's products using the following success metrics.
Overview
Alteris Therapeutics is 22 yrs old and is based in United States.
Alteris Therapeutics, Inc. Alteris focused on the discovery and development of therapeutics and vaccines against cancer targets. The company's cancer technologies were purchased by Celldex Therapeutics in 2005. Celldex merged with Avant Immunotherapeutics in 2008.www.celldextherapeutics.com.
Orca Therapeutics is based in Netherlands
Central to ORCA Therapeutics is the use of Oncolytic Replication Competent Agents (ORCA). These agents are typically derived from naturally occurring oncolytic viruses. Oncolytic viruses replicate selectively in cancer cells and kill these cells during replication. Upon destroying the infected cancer cells, progeny viruses are released that in turn will infect and kill adjacent cancer cells. A strongly enhanced anti-cancer effect is the result. In addition, oncolytic viruses can be used as efficient delivery agents - e.g. to express anti-cancer products at high levels in cancer cells- or as anti-cancer vaccines.
Demo Video
Leadership
Anthony Giordano (President)
Kees Groen (Chief Executive Officer)
Investors
Celldex Therapeutics and BioAdvance
Agentschap and Aglaia Oncology Funds
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Alteris Therapeutics has not claimed their profile.
Work for Alteris Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Alteris Therapeutics?
Claim your profile now.
Information not available because Orca Therapeutics has not claimed their profile.
Work for Orca Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Orca Therapeutics?
Claim your profile now.